<DOC>
	<DOCNO>NCT00126191</DOCNO>
	<brief_summary>The purpose study learn well chemotherapy regime include rituximab work treat patient Burkitt atypical Burkitt lymphoma .</brief_summary>
	<brief_title>Intensive Chemotherapy Rituximab Treatment Burkitt Lymphoma</brief_title>
	<detailed_description>- Patients place one two group , `` low risk '' `` high risk '' . `` Low risk '' disease define one area disease measure less 10cm normal blood test call LDH ( lactate hydrogenase ) . Patients fit `` low risk '' criterion consider `` high risk '' . - If patient `` low risk '' disease treatment cycle consist three cycle A . - If patient `` high risk '' disease receive Cycle A follow cycle B repeat . - Cycle A consist drug : rituximab , cyclophosphamide , oncovin , doxorubicin methotrexate ( R-CODOX-M ) . The treatment cycle approximately 14 day . A spinal tap perform day 1 day 3 cycle patient hospitalize day 11 day 13 . After patient 's blood count return normal ( usually around day 21 ) , next round treatment occur . - Cycle B consist drug : rituximab , ifosfamide , VP-16 ara-c ( IVAC ) . The treatment cycle approximately 5 day . A spinal tap perform day 4 blood count return normal patient start cycle A . - After patient finish treatment , re-evaluated CT scan PET scan determine whether remission . Every three month two year , blood test CT PET scan perform . Follow every 6 month two year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Isophosphamide mustard</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Mesna</mesh_term>
	<criteria>Histologically document Burkitt atypical Burkitt accord World Health Organization ( WHO ) criterion . Pathology must review Brigham Women 's Hospital ( BWH ) . Measurable evaluable disease : Disease reproducibly measurable two perpendicular dimension exam , compute tomography ( CT ) , radiograph , magnetic resonance imaging ( MRI ) . Disease present bone marrow biopsy consider evaluable disease . The following may use sole site measurable evaluable disease : *ascites , *pleural effusion , *bone lesion *central nervous system ( CNS ) disease . Age &gt; 18 Laboratory data ( within 2 week study registration ) : ANC &gt; 1500/ul ; platelet &gt; 100,000/ul ; creatinine &lt; 1.5 X normal ; creatinine clearance &gt; 60 ml/min ; bilirubin &lt; 1.5 X normal ; AST ALT &lt; 2.5 X normal ; alkaline phosphate &lt; 3 X normal ; HIV negative ; cardiac ejection fraction &gt; 50 % . Previous chemotherapy radiation therapy . Steroids less 72 hour duration impend oncologic emergency allow . Uncontrolled bacterial , fungal , viral infection . Concomitant malignancy exclude carcinoma situ cervix basal cell carcinoma skin . Serious comorbid disease . Clinically significant pulmonary symptomatology . In patient history symptomatic pulmonary disease , pulmonary function test ( PFTs ) document force expiratory volume 1 second ( FeV1 ) , force vital capacity ( FVC ) , total lung capacity ( TLC ) &gt; 60 % predicted carbon monoxide diffuse capacity lung ( DLCO ) &gt; 50 % predict . No clinically significant cardiac symptomatology . The cardiac ejection fraction must &gt; 50 % . Pregnancy . All male female reproductive potential must consent use effective form contraception study . Major surgery within previous 2 week .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Burkitt Lymphoma</keyword>
	<keyword>atypical Burkitt lymphoma</keyword>
	<keyword>Non-Hodgkin 's Lymphoma</keyword>
	<keyword>rituximab</keyword>
</DOC>